Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to Strong Sell at BidaskClub

BidaskClub lowered shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a sell rating to a strong sell rating in a research note published on Thursday morning, BidAskClub reports.

Several other research firms have also recently issued reports on LXRX. G.Research cut shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, December 11th. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a hold rating to a buy rating and set a $3.50 price objective for the company in a research report on Wednesday, February 12th. Citigroup cut shares of Lexicon Pharmaceuticals from a buy rating to a neutral rating and lifted their price objective for the stock from $3.00 to $4.00 in a research report on Friday, November 8th. Wedbush reaffirmed a buy rating and set a $17.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 23rd. Finally, Gabelli cut shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, December 11th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $6.30.

Lexicon Pharmaceuticals stock opened at $2.69 on Thursday. The stock has a market cap of $302.88 million, a P/E ratio of 1.98 and a beta of 1.07. The company has a fifty day simple moving average of $3.51 and a 200-day simple moving average of $3.22. Lexicon Pharmaceuticals has a 12-month low of $1.13 and a 12-month high of $8.39. The company has a current ratio of 8.11, a quick ratio of 8.01 and a debt-to-equity ratio of 1.42.

Large investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. raised its stake in Lexicon Pharmaceuticals by 755.6% during the 4th quarter. Meeder Asset Management Inc. now owns 9,857 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 8,705 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in Lexicon Pharmaceuticals by 40.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 4,746 shares in the last quarter. Raymond James Financial Services Advisors Inc. acquired a new stake in Lexicon Pharmaceuticals during the 4th quarter worth $60,000. Credit Suisse AG raised its stake in Lexicon Pharmaceuticals by 22.2% during the 4th quarter. Credit Suisse AG now owns 32,202 shares of the biopharmaceutical company’s stock worth $134,000 after acquiring an additional 5,853 shares in the last quarter. Finally, Virginia Retirement Systems ET AL acquired a new stake in Lexicon Pharmaceuticals during the 4th quarter worth $138,000. Hedge funds and other institutional investors own 96.31% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

See Also: How to identify percentage decliners

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.